An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
about
Natalizumab for relapsing remitting multiple sclerosisNatalizumab: A new treatment for relapsing remitting multiple sclerosisNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisExtended interval dosing of natalizumab in multiple sclerosis.Use of natalizumab in multiple sclerosis: current perspectives.Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Neuroimaging in multiple sclerosis: neurotherapeutic implications.Natalizumab in the treatment of multiple sclerosisCompared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.Natalizumab for the treatment of multiple sclerosis and Crohn's disease.Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check.Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.Fatalities in natalizumab treatment--a 'no go' for leukocyte recirculation approaches?
P2860
Q24235861-77B33933-E342-4259-AA49-DB49B753F9DBQ24683014-F67D26AD-E900-4358-86EB-5FE0DA23835EQ28277470-FB4D15E5-E6AB-460B-BCCF-A2196E9FB9DFQ31049360-28807801-2A3C-49D2-8FE9-92B6B1237BBCQ31114633-DBFCC200-4F55-4A33-9446-4BB590C73B21Q33573208-BA280D27-5112-415C-B8B7-7A9B50F83499Q33806032-38D06B07-A2F9-4358-9380-1F58D14770D9Q34409340-9F7BD0C5-7084-4E72-8E45-8D9C0126A0D1Q34630494-821CC825-AC91-4C75-ADA8-529A8B381E32Q36284072-0C9AB044-3B83-4A33-8622-574EB8574247Q36474344-0D92014F-6278-4A79-B12B-726F1E018D98Q36802680-466E96B7-4B05-415F-9FB9-0163E6E05DBAQ36927353-3C2F2504-E7B4-47B5-AA1E-C0F78B23EADCQ36951371-6525F539-D8B1-4C3E-B304-C0CCA8199487Q37562166-0A38B166-80EA-4B81-A311-013C033EAD00Q38167347-BBE20929-822C-49CE-8A60-EFB18A87A002Q38558344-06B16B3B-46C9-46A4-98A8-D93D7F245C4CQ48468772-E8C909CA-42D6-4315-BA96-8C5EC4284842
P2860
An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
An open-label safety and drug ...... ients with multiple sclerosis.
@en
An open-label safety and drug interaction study of natalizumab
@nl
type
label
An open-label safety and drug ...... ients with multiple sclerosis.
@en
An open-label safety and drug interaction study of natalizumab
@nl
prefLabel
An open-label safety and drug ...... ients with multiple sclerosis.
@en
An open-label safety and drug interaction study of natalizumab
@nl
P2093
P2860
P1476
An open-label safety and drug ...... ients with multiple sclerosis.
@en
P2093
A D Goodman
J L Giacchino
J S Grundy
J T Phillips
M A Libonati
T L Vollmer
P2860
P304
P356
10.1191/1352458504MS1084OA
P577
2004-10-01T00:00:00Z